NSE · SMSPHARMA.NS
SMS Pharmaceuticals Limited
₹516.70+₹30.90 (+6.36%)
SMS Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 1.58% below the high.
Loading market information…
NSE · GUJTHEM.NS · INR
Stock price, dividends
Quote as of Oct 30, 2026, 08:05 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Gujarat Themis Biosyn Limited’s quoted price sits in the upper half of its reported 52-week range, 22.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Gujarat Themis Biosyn Limited’s forward annual dividend is ₹0.67 per share, paid annual. The forward yield is 0.18% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds such as Rifamycin-S, an intermediate used in treatments for tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Another key product, Rifamycin-O, addresses ailments like traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Furthermore, they produce Lovastatin. Established in 1981, the company's operations are based out of Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹516.70+₹30.90 (+6.36%)
SMS Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 1.58% below the high.
₹840.10-₹53.30 (-5.97%)
Orchid Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 26.53% below the high.
₹416.20-₹2.60 (-0.62%)
Gufic Biosciences Limited’s quoted price sits in the upper half of its reported 52-week range, 11.03% below the high.
₹440.65-₹8.35 (-1.86%)
Aarti Drugs Limited’s quoted price sits in the upper half of its reported 52-week range, 17.48% below the high.
₹213.28+₹8.88 (+4.34%)
Hikal Limited’s quoted price sits in the upper half of its reported 52-week range, 18.28% below the high.
₹240.75-₹11.25 (-4.46%)
Kopran Limited’s quoted price sits in the upper half of its reported 52-week range, 18.62% below the high.
₹95.83-₹1.69 (-1.73%)
Themis Medicare Limited’s quoted price sits in the lower half of its reported 52-week range, 31.84% below the high.
₹86.91+₹7.17 (+8.99%)
Anuh Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 12.65% below the high.
